February 17, 2015

Teva Pharmaceuticals on Tuesday announced the launch of generic versions of Lovenox (enoxaparin sodium injection) as well as generic Zyvox (linezolid) injection. 

 

February 9, 2015

Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar. 

 

February 6, 2015

Prestige Brands will be resuming healthcare professional marketing programs in support of its Monistat vaginal treatments.

February 2, 2015

GlaxoSmithKline is gearing up for a Feb. 4 launch of its Flonase Allergy Relief (fluticasone propionate 50 mcg spray), an over-the-counter nasal spray indicated for relief of all nasal and eye-related allergy symptoms.

January 22, 2015

Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.

 

January 15, 2015

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline. 

January 12, 2015

Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. 

January 9, 2015

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

December 22, 2014

The Food and Drug Administration has granted accelerated approval to Opdivo (nivolumab), a new treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs.

December 11, 2014

Lupin Pharmaceuticals launched the authorized generic version of Celebrex capsules in 50-, 100-, 200- and 400-mg dosage strengths. 

December 10, 2014

Mylan on Wednesday launched its celecoxib capsules in 50-, 100-, 200- and 400-mg dosage strengths. The drug is one of the first available generic versions of Celebrex capsules from Pfizer.

December 4, 2014

Mylan on Thursday announced that its subsidiary, Mylan Labs, was granted tentative approval from the Food and Drug Administration for two dosages of abacavir/lamivudine tablets for oral suspension. 

December 4, 2014

Diplomat Pharmacy announced Wednesday that it has been selected to Pfizer's limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.

November 18, 2014

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries, on Tuesday announced that Health Canada has approved its application for PrTeva-Celecoxib, the generic equivalent of PrCelebrex.

November 13, 2014

 Janssen Pharmaceuticals announced that the Food and Drug Administration approved the company's supplemental new drug application for the once-monthly Invega Sustenna (paliperidone palmitate), an antipsychotic used to treat schizoaffective disorder as either monotherapy or adjunctive therapy. 

October 24, 2014

Pfizer on Thursday announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules.

October 6, 2014

Mylan announced the launch of its lamivudine and zidovudine tablets USP, in 150-mg dosage strength.

September 17, 2014

Mission Pharmacal on Tuesday participated in a White House Industry Leadership Roundtable discussion on ways to curb emissions of hydrofluorocarbons. 

August 25, 2014

ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection.

August 21, 2014

GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.

August 14, 2014

The Food and Drug Administration has announced approval for Belsomra (suvorexant) tablets, which are used to treat insomnia.

August 12, 2014

Sanofi on Tuesday announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop U.S., the company’s generics division. 

August 11, 2014

Mylan announced the launch of capecitabine tablets USP in 150-mg and 500-mg dosage strengths, a generic version of Xeloda tablets from Genentech.

July 30, 2014

Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.